Law Simon, Wong Kam-Ho, Kwok Ka-Fai, Chu Kent-Man, Wong John
Division of Esophageal Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
Ann Surg. 2004 Nov;240(5):791-800. doi: 10.1097/01.sla.0000143123.24556.1c.
This study aimed at: (1) documenting the evolution of surgical results of esophagectomy in a high-volume center, (2) identifying predictive factors of pulmonary complications and mortality, and (3) examining whether preoperative chemoradiation therapy would complicate postoperative recovery.
Pulmonary complications and mortality rate after esophagectomy remain substantial, and factors responsible have not been adequately studied. Neoadjuvant chemoradiation is widely used; it is hypothesized that this may lead to adverse postoperative outcome.
Prospectively collected data were used to analyze outcome in 421 patients with intrathoracic squamous cell esophageal cancer who underwent resection. Logistic regression analyses determined independent predictors of pulmonary complications and death. Two time periods were compared: period I (January 1990 to June 1995) and period II (July 1995 to December 2001). In the later period, neoadjuvant chemoradiation therapy was introduced.
Transthoracic resections were carried out in 83% of patients. Neoadjuvant chemoradiation was given to 42% of patients in period II. Major pulmonary complications occurred in 15.9%, and were primarily responsible for 55% of hospital deaths. Thirty-day and hospital mortality rates were 1.4% and 4.8%, respectively. Logistic regression analysis identified age, operation duration, and proximal tumor location as risk factors for pulmonary complications, whereas advanced age and higher blood loss were predictive of mortality. Chemoradiation did not lead to worse outcome. When period I and II were compared, hospital mortality rate reduced from 7.8% to 1.1%, P = 0.001, with correspondingly less blood loss (median blood loss was 700 ml (range: 200-2700 (period I) and 450 ml (range: 100-7000) (period II), P < 0.01).
A 1.1% mortality rate was achieved in the last 6 years of the study period. Preoperative chemoradiation did not result in worse outcome. Reduction in mortality rate correlated with decreased blood loss.
本研究旨在:(1)记录一家高容量中心食管癌切除术手术结果的演变;(2)确定肺部并发症和死亡率的预测因素;(3)研究术前放化疗是否会使术后恢复复杂化。
食管癌切除术后肺部并发症和死亡率仍然很高,相关因素尚未得到充分研究。新辅助放化疗被广泛应用;据推测,这可能导致不良的术后结果。
前瞻性收集的数据用于分析421例接受胸段鳞状细胞食管癌切除术患者的结果。逻辑回归分析确定肺部并发症和死亡的独立预测因素。比较了两个时间段:第一阶段(1990年1月至1995年6月)和第二阶段(1995年7月至2001年12月)。在后期引入了新辅助放化疗。
83%的患者进行了经胸切除术。第二阶段42%的患者接受了新辅助放化疗。主要肺部并发症发生率为15.9%,主要导致55%的医院死亡。30天和医院死亡率分别为1.4%和4.8%。逻辑回归分析确定年龄、手术时间和肿瘤近端位置是肺部并发症的危险因素,而高龄和失血较多是死亡的预测因素。放化疗并未导致更差的结果。比较第一阶段和第二阶段时,医院死亡率从7.8%降至1.1%,P = 0.001,失血量相应减少(第一阶段中位数失血量为700 ml(范围:200 - 2700),第二阶段为450 ml(范围:100 - 7000),P < 0.01)。
在研究期的最后6年中实现了1.1%的死亡率。术前放化疗并未导致更差的结果。死亡率的降低与失血量减少相关。